| Symbol
| LCN2
| contributors: mct - updated : 06-12-2015
|
| HGNC name
| lipocalin 2
|
| HGNC id
| 6526
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
| |
in ulcerative colitis | | tumoral
|
|
| --low
|
| |
in gastric cancer | | tumoral
|
|
| --over
|
|
consistently associated with invasive breast cancer  | | tumoral
|
|
|
| gain of function
| |
in multiple cancers, including breast, lung, and pancreas | | tumoral
|
|
| --over
|
| |
of SLC22A17 and LCN2 was found to be significantly associated with poor prognosis in glioma | |
Variant & Polymorphism
| 
| |
| Candidate gene
| useful biomarker of breast cancer (Lcn2 levels might be elevated in the urine of women with breast cancer; increase in the urine of women with metastatic breast cancer, suggesting that Lcn2 may have potential as a noninvasive biomarker for advanced breast cancer) |
| Marker
| increased plasma LCN2 levels during mild cognitive impairment (MCI) could be helpful in predicting the progression from MCI to Alzheimer disease |
|
HIC1-LCN2 axis may serve as a subtype-specific prognostic biomarker in triple-negative breast cancer |
|
urinary MMP9/LCN2 and ADAM12 are potential noninvasive biomarkers for gastric cancer, including early-stage disease |
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| digestive | liver | steatosis | |
| novel therapeutic drug target for the treatment of liver diseases associated with elevated fat accumulation and steatosis |
| |
|
| lipocalin-2-deficient mice have increased susceptibility to bacterial infections in the urinary tract |